Director, Liquid Biopsy and Early Diagnostic Strategy AstraZeneca
Liquid biopsy (LBx) testing has become an important tool to help inform the timely management and monitoring of cancer patients. Molecular laboratories are now looking to leverage existing in-house low to mid throughput NGS platforms and capabilities to provide this important testing for their referring clinicians, enabling more timely, efficient and cost-effective care. In this workshop we will: 1) Review the importance and role of localized LBx testing to support Biopharma's efforts to improve access to novel precision therapies and clinical trials. 2) Review the evaluation and clinical validation of a targeted, amplicon based NGS liquid biopsy panel by a leading academic medical center to help rapidly and efficiently identify clinically actionable biomarkers in NSCLC and Breast Cancer.
